LR3 IGF and slin together

[oswaldosalcedo]

that study is from 1993.
(Biochem. J. (1993) 291, 781-786)

if you substract the fat from the gain for LR3 and SLIN are almost the same.

AGENT: GR PROT CARCASS ANIMALS (Rats):

INSULIN------------192

IGF1---------------206

DES IGF1-----------207

LR3----------------211

NO BIG DIFFERENCE WITH SLIN.


------------------------------------------

AND FOR LR3 STUDIES DONE IN HUMANS:

Dear Mr. Salcedo,

In reply to your question, there are no studies (LR3) in man to the best of my knowledge. Some of the IGF-I analogues have been found to be potent mitogens. What is the reason you asked? Do you have any patients?

We are at present performing a worldwide survey on the prevalence of malignancy in patients with IGF-I deficiency and their family relatives. If you see or know such patients I would appreciate your cooperation in providing us data on a simple questionnaire.
Please reply and we shall send you further details.

Best regards,

Zvi Laron, MD
_______________________
Prof. Zvi Laron
Endocrinology and Diabetes Research Unit,
Schneider Children's Medical Center
Petah-Tikva 49202
Israel
Fax: 972-3-9222996
--------------------------------------------------

he is one of the world leaders in igf 1 studies.

.

[JohnnyB]

that study is from 1993.
(Biochem. J. (1993) 291, 781-786)

if you substract the fat from the gain for LR3 and SLIN are the same.

AGENT: GR PROT CARCASS ANIMALS (Rats):

INSULIN------------192

IGF1---------------206

DES IGF1-----------207

LR3----------------211

NO BIG DIFFERENCE WITH SLIN.

------------------------------------------

AND FOR LR3 STUDIES DONE IN HUMANS:

Dear Mr. Salcedo,

In reply to your question, there are no studies in man to the best of my knowledge. Some of the IGF-I analogues have been found to be potent mitogens. What is the reason you asked? Do you have any patients?

We are at present performing a worldwide survey on the prevalence of malignancy in patients with IGF-I deficiency and their family relatives. If you see or know such patients I would appreciate your cooperation in providing us data on a simple questionnaire.
Please reply and we shall send you further details.

Best regards,

Zvi Laron, MD
_______________________
Prof. Zvi Laron
Endocrinology and Diabetes Research Unit,
Schneider Children's Medical Center
Petah-Tikva 49202
Israel
Fax: 972-3-9222996

HE IS ONE OF THE WORLD LEADERS ON IGF1 STUDIES ON HUMANS.

Do you have access to his studies? It says he is the leader in studies on humans with IGF-1, I'm looking for studies done with LR3 IGF-1, not IGF-1. There is a differance, that is why I like calling it LR3, instead of IGF-1. There are plenty of studies in IGF-1 in humans, but I've yet to see any done on humans with LR3 IGF-1. So if you have some I'd love to read them.

JohnnyB

[oswaldosalcedo]

..........................................
Mech Ageing Dev. 2005 Feb;126(2):305-7.


Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity?

Laron Z.

Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, WHO Collaborating Center for the Study of Diabetes in Youth, Tel Aviv University, Tel Aviv, Israel.
Present knowledge on the effects of growth hormone (GH) and insulin-like growth factor-I (IGF-I) deficiency on aging and lifespan are controversial. Studying untreated patients with either isolated GH deficiency due to GH gene deletion, patients with multiple pituitary hormone deficiency due to PROP-1 gene mutation and patients with isolated IGF-I deficiency due to deletions or mutations of the GH receptor gene (Laron syndrome); it was found, that these patients despite signs of early aging (wrinkled skin, obesity, insulin resistance and osteopenia) have a long life span reaching ages of 80-90 years. Animal models of genetic GH deficiencies such as Snell mice (Pit-1 gene mutations) the Ames mice (PROP-1 gene mutation) and the Laron mice (GH receptor gene knock-out) have a statistically significant higher longevity compared to normal controls. On the contrary, mice transgenic for GH and acromegalic patients secreting high amounts of GH have premature death. Those data raise the question whether pharmacological GH administration to adults is deleterious, in contrast to policies advocating such therapies.

[oswaldosalcedo]

Rev Endocr Metab Disord. 2002 Dec;3(4):347-55.


Growth hormone insensitivity (Laron syndrome).

Laron Z.